Editas Medicine Inc - Company Profile
Powered by
All the data and insights you need on Editas Medicine Inc in one report.
- Save hours of research time and resources with
our up-to-date Editas Medicine Inc Strategy Report
- Understand Editas Medicine Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Editas Medicine Inc (Editas Medicine) is a discovery phase biotechnology company that develops therapies based on CRISPR- gene editing technology using Cas9 and Cas12a enzymes for the treatments of serious diseases. Improved financial performance, research and development activities and genome editing platform are its strengths, even as, increasing trade receivables is a major cause of concern to the company. Although intense competition, dependence on third party manufacturers and government regulations could hamper the company's growth prospects, Editas Medicine could benefit from strategic initiatives, unmet clinical need for the treatment of Leber Congenital Amaurosis and global outlook of genomic sequencing industry.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer